CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to INCY

Phase 3

Development Phase

5

Upcoming Catalysts

1

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Q4 '27
INCYPhase 2

Ruxolitinib Phase 2 Est. Readout

Ruxolitinib
Q4 2027~Q
CT.gov
00%
Q3 '27
INCYPhase 2

Ruxolitinib Phase 2 Est. Readout

Ruxolitinib
Q3 2027~Q
CT.gov
00%
Jul '27
INCYPhase 2

Ruxolitinib Phase 2 Est. Readout

Ruxolitinib
Jul 2027~
CT.gov
00%
Q2 '27
INCYPhase 2

Ruxolitinib Phase 2 Est. Readout (MAGIC V)

Ruxolitinib
Q2 2027~Q
CT.gov
00%
Jan '27
INCYPhase 2

Ruxolitinib Phase 2 Est. Readout

Ruxolitinib
Jan 2027~
CT.gov
00%
Development History
Nov '26
INCYPhase 2

Ruxolitinib Phase 2 Est. Readout

Ruxolitinib
Nov 2026~
CT.gov
00%
Competitive Landscape

2 competitors in MPN (Myeloproliferative Neoplasms)

View Full Landscape
Drug Information

Target Indication

MPN (Myeloproliferative Neoplasms)

Clinical Trial

NCT01348490

Last updated: 12/29/2025

Patent & Exclusivity
ActiveRLD

Latest Patent Expiry

May 5, 2041(14y 6m)

Patents Listed

54

Exclusivity

I-896NPPPEDODE*PEDM-285ODE-238ODE-373PED

Application

NDA 217180
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.